His main research concerns Leukemia, Cancer research, Myeloid leukemia, Immunology and Myeloid. The concepts of his Leukemia study are interwoven with issues in Fluorescence in situ hybridization, Stem cell and Gene mutation. His Cancer research research is multidisciplinary, incorporating elements of Germline mutation, Cellular differentiation, Oncogene, CEBPA and Myeloid-Lymphoid Leukemia Protein.
His Myeloid leukemia research includes elements of Bioinformatics, Mutation, Minimal residual disease, Myelodysplastic syndromes and NPM1. The various areas that Lars Bullinger examines in his Immunology study include Internal medicine, Oncology and Gene expression profiling. His study in the field of [email protected] is also linked to topics like Untreated Chronic Lymphocytic Leukemia.
Lars Bullinger focuses on Myeloid leukemia, Cancer research, Leukemia, Internal medicine and Oncology. His research in Myeloid leukemia intersects with topics in Myeloid, Gene, NPM1 and Gene expression profiling. His Gene expression profiling study combines topics in areas such as DNA microarray and Bioinformatics.
His Cancer research study incorporates themes from Progenitor cell, Haematopoiesis, Stem cell, Gene expression and microRNA. His research brings together the fields of Bone marrow and Leukemia. His Internal medicine study frequently links to related topics such as Gene mutation.
His primary areas of investigation include Cancer research, Myeloid leukemia, Internal medicine, Oncology and Myeloid. As a member of one scientific family, Lars Bullinger mostly works in the field of Cancer research, focusing on T cell and, on occasion, CD8. Specifically, his work in Myeloid leukemia is concerned with the study of Midostaurin.
His Transplantation, Cumulative incidence, Disease and Hematopoietic stem cell transplantation study in the realm of Internal medicine connects with subjects such as In patient. Lars Bullinger studied Oncology and Gene mutation that intersect with Cytogenetics and Cytarabine. In his study, which falls under the umbrella issue of Myeloid, Synthetic lethality is strongly linked to Leukemia.
Myeloid leukemia, Myeloid, Cancer research, Leukemia and Internal medicine are his primary areas of study. His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Chromatin, Cell cycle, Regulation of gene expression and Gene. His studies deal with areas such as Haematopoiesis, Epigenetics, Disease and Bone marrow as well as Myeloid.
He has included themes like Synthetic lethality, DNA repair, Progenitor cell, Stem cell and Transcriptome in his Cancer research study. The study incorporates disciplines such as Receptor tyrosine kinase and Downregulation and upregulation in addition to Leukemia. His Internal medicine research incorporates elements of Genotyping and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner;Stephan Stilgenbauer;Axel Benner;Elke Leupolt.
The New England Journal of Medicine (2000)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil;Moritz Gerstung;Lars Bullinger;Verena I Gaidzik.
The New England Journal of Medicine (2016)
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Richard F. Schlenk;Konstanze Döhner;Jürgen Krauter;Stefan Fröhling.
The New England Journal of Medicine (2008)
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
Lars Bullinger;Konstanze Döhner;Eric Bair;Stefan Fröhling.
The New England Journal of Medicine (2004)
VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia
Alexander Kröber;Till Seiler;Till Seiler;Axel Benner;Axel Benner;Lars Bullinger;Lars Bullinger.
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
Konstanze Döhner;Richard F Schlenk;Marianne Habdank;Claudia Scholl.
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka;Richard F. Schlenk;Verena I. Gaidzik;Marianne Habdank.
Journal of Clinical Oncology (2010)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt;Nan Zhu;Amit U. Sinha;Sridhar Vempati.
Cancer Cell (2011)
Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations
Tobias Rausch;David T.W. Jones;Marc Zapatka;Adrian M. Stütz.
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Jan Krönke;Emma C. Fink;Emma C. Fink;Paul W. Hollenbach;Kyle J. MacBeth.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: